BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:AVZO-021 readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of AVZO-021\, from ClinicalTrials.gov estima
 tes.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT05867251-9111@assetmemo.bio
DTSTAMP:20261121T005439Z
DTSTART;VALUE=DATE:20280131
DTEND;VALUE=DATE:20280201
SUMMARY:AVZO-021: Phase 1/2 readout est. (NCT05867251)
DESCRIPTION:AVZO-021\, phase 1/2\, HR+/HER2- Metastatic Breast Cancer.\nStu
 dy: Study of AVZO-021 in Patients With Advanced Solid Tumors\nEstimated pr
 imary completion: 31 January 2028. This is a ClinicalTrials.gov estimate\,
  not a confirmed readout date\, and it can move.\nDrug page: https://asset
 memo.bio/drug/avzo-021#upcoming-events\nRegistry record: https://clinicalt
 rials.gov/study/NCT05867251
URL:https://assetmemo.bio/drug/avzo-021#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06998407-9111@assetmemo.bio
DTSTAMP:20261121T005439Z
DTSTART;VALUE=DATE:20280831
DTEND;VALUE=DATE:20280901
SUMMARY:AVZO-021: Phase 1/2 readout est. (NCT06998407)
DESCRIPTION:AVZO-021\, phase 1/2\, HR+/HER2- Metastatic Breast Cancer.\nStu
 dy: ORION-1: Study of AVZO-023 as a Single Agent and in Combination With A
 VZO-021\, and/or Endocrine Therapy in Advanced Solid Tumors\nEstimated pri
 mary completion: August 2028. This is a ClinicalTrials.gov estimate\, not 
 a confirmed readout date\, and it can move.\nDrug page: https://assetmemo.
 bio/drug/avzo-021#upcoming-events\nRegistry record: https://clinicaltrials
 .gov/study/NCT06998407
URL:https://assetmemo.bio/drug/avzo-021#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
